newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - BIOAGE LABS INC

  • Financial Performance:

    • Cash position stands at just over $350 million, providing a runway extending through 2029.
    • Current capital is allocated to fund Phase 2 trials for NLRP3 (BGE-102) across multiple indications (QUAL-CV, Quell-DME, and an undisclosed indication) and APJ agonist programs through proof-of-concept.
    • No specific revenue or profit margins were discussed as the company remains in clinical development stages.
  • Guidance and Future Outlook:

    • BGE-102 (NLRP3 inhibitor) Phase 2 QUAL-CV trial data targeted for release by the end of the current year.
    • Quell-DME (Diabetic Macular Edema) Phase 2 data readout expected in the second half of next year.
    • Investigational New Drug (IND) filing for one APJ agonist program targeted for the end of the current year.
    • Management is pivoting near-term clinical focus toward ophthalmology (DME) and obesity/inflammation, with a strategy to re-evaluate cardiovascular outcomes trials based on future market signals (e.g., competitor data from Artemis or Ventrix).
  • Business Segments and Product Lines:

    • BGE-102 (NLRP3 Inhibitor): Oral, best-in-class potential candidate; Phase 1 data showed 98% trough inhibition of IL-1β with placebo-like tolerability and superior brain/retina penetration. Currently running three dose levels in Phase 2.
    • APJ Agonists: Two programs (oral and parenteral) targeting obesity and longevity; preclinical data suggests potential to double weight loss and restore body composition when combined with GLP-1.
    • Partnerships: Active collaborations with Eli Lilly (therapeutic antibodies for aging targets) and Novartis (early-stage target discovery linking aging data with exercise intervention).
    • Pipeline Strategy: Utilizing NLRP3's upstream inhibition of IL-1β and IL-18 to address sterile inflammation, with a specific "beachhead" strategy in ophthalmology (DME, geographic atrophy, uveitic macular edema).
  • Market and Competitive Landscape:

    • Differentiation for BGE-102 lies in a novel binding site distinct from historical NLRP3 inhibitors (e.g., Pfizer, Ventix), allowing for dual inhibition and disassembly of the inflammasome complex.
    • Management cites the failure of the Zeus trial (IL-6 inhibitor) as evidence that targeting downstream cytokines (IL-6) is less effective than upstream mechanisms (NLRP3/IL-1β) for modulating cardiovascular outcomes.
    • The oral administration of BGE-102 offers a value proposition over standard-of-care intravitreal injections, addressing patient resistance to frequent eye injections and offering a treatment option for VEGF-refractory patients.
    • The company is monitoring competitor NLRP3 programs (e.g., Lilly's Ventrix) and the Artemis trial outcomes to determine potential future entry into cardiovascular outcomes trials.
  • Risks and Challenges:

    • Strategic shift away from immediate cardiovascular outcomes trials due to high capital requirements and risk tolerance, despite the biological plausibility of NLRP3 in ASCVD.
    • Dependence on successful Phase 2 readouts for BGE-102 in obesity and DME to de-risk broader indications and justify future funding.
    • Historical safety concerns with previous APJ programs (idiosyncratic liver injury), though management asserts the new chemical entities have distinct chemotypes and lower dosing requirements to mitigate this risk.
    • Competitive pressure in the anti-inflammatory and obesity markets, requiring clear differentiation in efficacy profiles.
  • Management Commentary and Tone:

    • Tone was confident and technically detailed, emphasizing the robust biological differentiation of BGE-102 (complete 24-hour target suppression).
    • Management expressed strong conviction in the NLRP3 platform's ability to address "sterile inflammation" across cardiometabolic and ocular diseases.
    • Executives demonstrated strategic agility by pivoting from the large-scale cardiovascular market to more feasible proof-of-concept indications (ophthalmology, obesity) while maintaining readiness to return to cardiovascular outcomes if external data warrants it.
  • Analyst Questions and Answers:

    • Differentiation vs. Competitors: Analyst asked about NLRP3 competition; Management clarified BGE-102 uses a novel chemotype and binding site compared to ATPase pocket inhibitors, achieving superior tissue distribution and deeper target inhibition.
    • Impact of Zeus Trial: Analyst questioned the implications of the Zeus failure; Management concluded IL-6 is likely too far downstream to be a causal target, reinforcing BGE-102's upstream approach, but noted they will not pursue a standalone ASCVD outcomes trial immediately.
    • Biomarker Efficacy: Analyst requested details on Phase 1 biomarkers; Management reported 86% reduction in CRP and concordant drops in IL-6 and fibrinogen, supporting the rationale for the Phase 2 QUAL-CV trial.
    • Obesity Program: Analyst asked about the APJ program's safety profile; Management explained the new oral program uses a distinct chemistry and significantly lower daily doses (<100mg) compared to the discontinued 300mg+ Amgen-derived compound to eliminate liver safety risks.
    • DME Strategy: Analyst queried the integration of oral therapy with VEGF standard of care; Management highlighted the "watch and wait" patient segment resistant to injections and the potential for BGE-102 to provide monotherapy or combination benefits in refractory cases.
  • Other Key Points:

    • BioAge utilizes a proprietary human aging platform with data from biobanks tracking participants from middle age to death for phenotypic and genetic analysis.
    • The company emphasizes the "de novo" nature of their NLRP3 discovery, having blocked the known ATPase pocket to find alternative binding sites.
    • Management indicated that while they are focusing on ophthalmology now, the underlying preparation for cardiovascular outcomes trials remains intact should market conditions change.
Company
BIOAGE LABS INC
Keywords
BIOAGE LABS INC